{"id":43559,"date":"2020-11-11T03:11:56","date_gmt":"2020-11-11T01:11:56","guid":{"rendered":"https:\/\/newserver.fyb.de\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/"},"modified":"2020-11-11T03:11:56","modified_gmt":"2020-11-11T01:11:56","slug":"catalym-euro-50-million-series-b-for-development-in-immuno-oncology","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/","title":{"rendered":"CatalYm: Euro 50 million Series\u2011B for development in immuno-oncology"},"content":{"rendered":"

Munich, Germany \u2014 Cata\u00adlYm, an inno\u00adva\u00adtive biotech company deve\u00adlo\u00adping novel immu\u00adno\u00adthe\u00adrapy approa\u00adches against cancer, has successfully closed its \u20ac50 million Series B finan\u00adcing. The finan\u00adcing consor\u00adtium, led by lead inves\u00adtor Vesa\u00adlius Bioca\u00adpi\u00adtal III<\/strong>, also includes Novar\u00adtis Venture Fund (NVF)<\/strong>, Wachs\u00adtums\u00adfonds Bayern, copa\u00adrion<\/strong> and foun\u00adding inves\u00adtors Forbion <\/strong>and BioGe\u00adnera\u00adtion Ventures<\/strong>. Repre\u00adsen\u00adta\u00adti\u00adves from Vesa\u00adlius, NVF and Bayern Kapi\u00adtal will join the advi\u00adsory board as new members.<\/p>\n

The funding combi\u00adned with the strong commit\u00adment of exis\u00adting and new venture capi\u00adtal inves\u00adtors enables the all-important further deve\u00adlo\u00adp\u00adment of anti\u00adbo\u00addies in the field of immuno-onco\u00adlogy. \u2014 Baker McKen\u00adzie<\/strong> \u2018s Life Scien\u00adces team, led by Julia Braun, advi\u00adsed Cata\u00adlYm on all legal aspects of the Series B financing.<\/p>\n

\u201cThe times of COVID-19 in parti\u00adcu\u00adlar are an exci\u00adting period for our client and the indus\u00adtry as a whole. Toge\u00adther with our client and our team of specia\u00adli\u00adzed biotech\u00adno\u00adlogy and life scien\u00adces lawy\u00aders, we successfully secu\u00adred funds for further rese\u00adarch in the health\u00adcare sector with this tran\u00adsac\u00adtion,\u201d commen\u00adted Coun\u00adsel Julia Braun.<\/p>\n

Cata\u00adlYm is a biophar\u00admaceu\u00adti\u00adcal company deve\u00adlo\u00adping novel cancer immu\u00adno\u00adthe\u00adra\u00adpies targe\u00adting growth and diffe\u00adren\u00adtia\u00adtion factor 15 (GDF-15). The company was estab\u00adlished with start-up funding from Forbion and BGV in 2016 as a spin-off of the Univer\u00adsity Women\u2019s Hospi\u00adtal W\u00fcrz\u00adburg and based on the work of Prof. Dr. J\u00f6rg Wisch\u00adhusen. Cata\u00adlYm is led by an expe\u00adri\u00aden\u00adced manage\u00adment team with exten\u00adsive exper\u00adtise in immuno-onco\u00adlogy drug deve\u00adlo\u00adp\u00adment and deal expe\u00adri\u00adence, and supported by inter\u00adna\u00adtio\u00adnal venture capitalists.<\/p>\n

Baker McKen\u00adzie\u2019s Corporate\/M&A and Life Scien\u00adces team regu\u00adlarly advi\u00adses large phar\u00admaceu\u00adti\u00adcal, finan\u00adcial inves\u00adtor and early stage biotech\u00adno\u00adlogy compa\u00adnies on dome\u00adstic and inter\u00adna\u00adtio\u00adnal health\u00adcare tran\u00adsac\u00adtions. Most recently, Baker McKen\u00adzie advi\u00adsed, among others, Casdin Capi\u00adtal as lead inves\u00adtor in DNA Scrip\u00adt\u2019s USD 50 million exten\u00added Series\u2011B finan\u00adcing round, Chr. Hansen Holding on its acqui\u00adsi\u00adtion of Jenne\u00adwein, Cure\u00adVac on its stra\u00adte\u00adgic mRNA tech\u00adno\u00adlogy colla\u00adbo\u00adra\u00adtion with GSK, LSP Life Science Part\u00adners on a USD 38.5 million Series\u2011B finan\u00adcing in DNA Script, Gala\u00adpa\u00adgos on a 10-year global rese\u00adarch and deve\u00adlo\u00adp\u00adment colla\u00adbo\u00adra\u00adtion with Gilead, Hita\u00adchi Chemi\u00adcal Company, Tokyo, in the acqui\u00adsi\u00adtion of German apceth Biopharma, Forbion as lead inves\u00adtor in a EUR 17 million Series\u2011C equity finan\u00adcing of Omei\u00adcos Thera\u00adpeu\u00adtics and in a USD 54 million Series\u2011A finan\u00adcing of Gotham Thera\u00adpeu\u00adtics Corpo\u00adra\u00adtion, Mundi\u00adpharma in the sale of its Limburg manu\u00adfac\u00adtu\u00adring facility.<\/p>\n

Legal advi\u00adsor Cata\u00adlYm: Baker McKenzie<\/strong>
\nLead: Corporate\/M&A: Julia Braun (Coun\u00adsel, Munich)
\nCorporate\/M&A: Bert\u00adhold Hummel (Part\u00adner, Munich), Michelle Karrer, Dr. Julia Rossi\u00e9 (both Asso\u00adciate, Munich)
\nPublic Law: Anahita Thoms (Part\u00adner, D\u00fcssel\u00addorf), Alex\u00adan\u00adder Ehrle (Asso\u00adciate, Berlin)
\nAnti\u00adtrust & Trade: Dr. Jonas Brueck\u00adner (Coun\u00adsel, Berlin)
\nPharma: Dr. Chris\u00adtian Burholt (Part\u00adner, Berlin)<\/p>\n

About Baker McKenzie<\/strong>
\nBaker McKen\u00adzie advi\u00adses clients to successfully deal with the chal\u00adlenges of globa\u00adliza\u00adtion. We solve complex legal problems across natio\u00adnal borders and legal fields. Our unique culture \u2014 grown over 70 years \u2014 enables our 13,000 employees to under\u00adstand local markets while opera\u00adting inter\u00adna\u00adtio\u00adnally. We use the trus\u00adting and friendly coope\u00adra\u00adtion in our inter\u00adna\u00adtio\u00adnal network for the bene\u00adfit of our clients.<\/p>\n

In Germany, around 200 lawy\u00aders with proven profes\u00adsio\u00adnal exper\u00adtise and inter\u00adna\u00adtio\u00adnal expe\u00adri\u00adence repre\u00adsent the inte\u00adrests of their clients at the offices in Berlin, D\u00fcssel\u00addorf, Frankfurt\/Main and Munich. As one of the leading German law firms, Baker McKen\u00adzie advi\u00adses natio\u00adnal and inter\u00adna\u00adtio\u00adnal compa\u00adnies and insti\u00adtu\u00adti\u00adons in all areas of commer\u00adcial law.<\/p>\n","protected":false},"excerpt":{"rendered":"

Munich, Germany \u2014 Cata\u00adlYm, an inno\u00adva\u00adtive biotech company deve\u00adlo\u00adping novel immu\u00adno\u00adthe\u00adrapy approa\u00adches against cancer, has successfully closed its \u20ac50 million Series B finan\u00adcing. The finan\u00adcing consor\u00adtium, led by lead inves\u00adtor Vesa\u00adlius Bioca\u00adpi\u00adtal III, also includes Novar\u00adtis Venture Fund (NVF), Wachs\u00adtums\u00adfonds Bayern, copa\u00adrion and foun\u00adding inves\u00adtors Forbion and BioGe\u00adnera\u00adtion Ventures. Repre\u00adsen\u00adta\u00adti\u00adves from Vesa\u00adlius, NVF and Bayern [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":35554,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1369,1373],"tags":[],"class_list":["post-43559","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"\nCatalYm: Euro 50 million Series-B for development in immuno-oncology - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CatalYm: Euro 50 million Series-B for development in immuno-oncology - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Munich, Germany \u2014 Cata\u00adlYm, an inno\u00adva\u00adtive biotech company deve\u00adlo\u00adping novel immu\u00adno\u00adthe\u00adrapy approa\u00adches against cancer, has successfully closed its \u20ac50 million Series B finan\u00adcing. The finan\u00adcing consor\u00adtium, led by lead inves\u00adtor Vesa\u00adlius Bioca\u00adpi\u00adtal III, also includes Novar\u00adtis Venture Fund (NVF), Wachs\u00adtums\u00adfonds Bayern, copa\u00adrion and foun\u00adding inves\u00adtors Forbion and BioGe\u00adnera\u00adtion Ventures. Repre\u00adsen\u00adta\u00adti\u00adves from Vesa\u00adlius, NVF and Bayern […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-11T01:11:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"840\" \/>\n\t<meta property=\"og:image:height\" content=\"595\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"CatalYm: Euro 50 million Series\u2011B for development in immuno-oncology\",\"datePublished\":\"2020-11-11T01:11:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/\"},\"wordCount\":546,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Lawyers, tax consultants, auditors\",\"Investors\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/\",\"url\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/\",\"name\":\"CatalYm: Euro 50 million Series-B for development in immuno-oncology - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg\",\"datePublished\":\"2020-11-11T01:11:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg\",\"width\":840,\"height\":595},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CatalYm: Euro 50 million Series\u2011B for development in immuno-oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CatalYm: Euro 50 million Series-B for development in immuno-oncology - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/","og_locale":"en_US","og_type":"article","og_title":"CatalYm: Euro 50 million Series-B for development in immuno-oncology - FYB Financial Yearbook","og_description":"Munich, Germany \u2014 Cata\u00adlYm, an inno\u00adva\u00adtive biotech company deve\u00adlo\u00adping novel immu\u00adno\u00adthe\u00adrapy approa\u00adches against cancer, has successfully closed its \u20ac50 million Series B finan\u00adcing. The finan\u00adcing consor\u00adtium, led by lead inves\u00adtor Vesa\u00adlius Bioca\u00adpi\u00adtal III, also includes Novar\u00adtis Venture Fund (NVF), Wachs\u00adtums\u00adfonds Bayern, copa\u00adrion and foun\u00adding inves\u00adtors Forbion and BioGe\u00adnera\u00adtion Ventures. Repre\u00adsen\u00adta\u00adti\u00adves from Vesa\u00adlius, NVF and Bayern […]","og_url":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2020-11-11T01:11:56+00:00","og_image":[{"width":840,"height":595,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"CatalYm: Euro 50 million Series\u2011B for development in immuno-oncology","datePublished":"2020-11-11T01:11:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/"},"wordCount":546,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg","articleSection":["General","Featured","News","Lawyers\/Tax-advisors\/Auditors","Lawyers, tax consultants, auditors","Investors","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/","url":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/","name":"CatalYm: Euro 50 million Series-B for development in immuno-oncology - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg","datePublished":"2020-11-11T01:11:56+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/11\/a-versalius-3.jpg","width":840,"height":595},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/catalym-euro-50-million-series-b-for-development-in-immuno-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"CatalYm: Euro 50 million Series\u2011B for development in immuno-oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43559"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43559\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/35554"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}